{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:00:08Z","timestamp":1776106808415,"version":"3.50.1"},"reference-count":63,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Evidence-based medicine (EBM) has created a revolutionary system for disseminating a scientific method. However, the scientific rigor of early EBM did not demonstrate any concern for ethics in the management of venous thromboembolism (VTE) and atrial fibrillation (AF). We critically reviewed whether EBM and ethical principles have always converged, focusing on the development and use of anticoagulants, by analyzing key trials in the treatment and prevention of those conditions. Moreover, we aimed to explore whether methodological rigor has sometimes overshadowed clinical ethics, particularly in the context of placebo-controlled trials. In our opinion, even if randomized clinical trials (RCTs) are considered the first step in the hierarchy of EBM, several of these appear unjustified, as observational studies had already indicated that anticoagulants (heparins and anti-vitamin K drugs [VKA]) were considered effective in the treatment and prevention of thrombotic diseases, such as VTE and AF. The use of a placebo was often unethical. This has caused unjustified mortality and morbidity to many people when a placebo has been used as a control. Even the methodology in favor of the non-inferiority margin is questionable, as it is considered satisfactory to maintain at least half of the efficacy of the current drug. In other words, a bonus for the new medicines seems to be always generous, and in the future, biocreep phenomenon is destined to be dangerous. The belief that only RCTs, even if of paramount importance, produce trustworthy results and that observational studies are misleading can lead to a disadvantage in patient care, clinical investigation, and the education of health care professionals (visual abstract).<\/jats:p>","DOI":"10.1055\/a-2716-5675","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T23:08:17Z","timestamp":1761260897000},"source":"Crossref","is-referenced-by-count":1,"title":["Anticoagulants: Evidence-Based Medicine, Not Always Ethical"],"prefix":"10.1055","author":[{"given":"Francesco","family":"Marongiu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Cagliari, Cagliari, Italy"},{"name":"Fondazione Arianna, Anticoagulazione.it, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Mameli","sequence":"additional","affiliation":[{"name":"Transfusion Medicine Unit, Azienda Socio Sanitaria Locale n. 6 San Gavino, Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Marongiu","sequence":"additional","affiliation":[{"name":"Transfusion Medicine Unit, Azienda Socio Sanitaria Locale n. 6 San Gavino, Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Barcellona","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, Internal Medicine, University of Cagliari, Cagliari, Italy"},{"name":"Haemostasis and Thrombosis Departmental Unit, Teaching Hospital of Cagliari, Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"17","key":"ref1","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1001\/jama.1992.03490170092032","article-title":"Evidence-based medicine. A new approach to teaching the practice of medicine","volume":"268","author":"Evidence-Based Medicine Working Group","year":"1992","journal-title":"JAMA"},{"issue":"4582","key":"ref2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/bmj.2.4582.769","article-title":"STREPTOMYCIN treatment of pulmonary tuberculosis","volume":"2","year":"1948","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3181\/00379727-55-14461","article-title":"Streptomycin. Substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria","volume":"55","author":"A Schatz","year":"1944","journal-title":"Proc Soc Exp Biol Med"},{"issue":"4541","key":"ref4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/bmj.1.4541.87","article-title":"Streptomycin; a valuable anti-tuberculosis agent","volume":"1","author":"W H Feldman","year":"1948","journal-title":"BMJ"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1056\/NEJM199408113310611","article-title":"The continuing unethical use of placebo controls","volume":"331","author":"K J Rothman","year":"1994","journal-title":"N Engl J Med"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/107602960100700403","article-title":"The oral anticoagulant saga: Past, present, and future","volume":"7","author":"B M Duxbury","year":"2001","journal-title":"Clin Appl Thromb Hemost"},{"issue":"10","key":"ref7","first-page":"796","article-title":"Heparin and thrombosis: Harvey Lecture, November 28, 1940","volume":"17","author":"C H Best","year":"1941","journal-title":"Bull N Y Acad Med"},{"issue":"6842","key":"ref8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(54)92504-0","article-title":"Treatment of venous thrombosis with anticoagulants; review of 1135 cases","volume":"267","author":"J Marks","year":"1954","journal-title":"Lancet"},{"issue":"5361","key":"ref9","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/bmj.2.5361.830","article-title":"Pulmonary embolism","volume":"2","author":"M T Morrell","year":"1963","journal-title":"BMJ"},{"issue":"7138","key":"ref10","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(60)92299-6","article-title":"Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial","volume":"1","author":"D W Barritt","year":"1960","journal-title":"Lancet"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003495-197612010-00002","article-title":"Antithrombotic drugs: part I","volume":"12","author":"A S Gallus","year":"1976","journal-title":"Drugs"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1365-2044.1976.tb11905.x","article-title":"Pulmonary embolism. Prophylaxis diagnosis and treatment","volume":"31","author":"D G Price","year":"1976","journal-title":"Anaesthesia"},{"issue":"09","key":"ref13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/014107688107400911","article-title":"Value of anticoagulants in the treatment of pulmonary embolism: a discussion paper","volume":"74","author":"P Egermayer","year":"1981","journal-title":"J R Soc Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"10B","DOI":"10.1016\/S0735-1097(86)80003-1","article-title":"Pharmacology of heparin and warfarin","volume":"8","author":"S Wessler","year":"1986","journal-title":"J Am Coll Cardiol"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.0954-6820.1969.tb07351.x","article-title":"Atrial fibrillation. I. A study of atrial thrombosis and systemic embolism in a necropsy material","volume":"185","author":"H Aberg","year":"1969","journal-title":"Acta Med Scand"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0002-9149(77)90064-9","article-title":"Influence of etiology of atrial fibrillation on incidence of systemic embolism","volume":"40","author":"R C Hinton","year":"1977","journal-title":"Am J Cardiol"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/WNL.28.10.973","article-title":"Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study","volume":"28","author":"P A Wolf","year":"1978","journal-title":"Neurology"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.STR.11.5.433","article-title":"Management of cerebral embolism of cardiac origin","volume":"11","author":"J D Easton","year":"1980","journal-title":"Stroke"},{"issue":"01","key":"ref19","first-page":"106","article-title":"Arterial embolism","volume":"124","author":"R C Darling","year":"1967","journal-title":"Surg Gynecol Obstet"},{"issue":"8631","key":"ref20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","article-title":"Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study","volume":"1","author":"P Petersen","year":"1989","journal-title":"Lancet"},{"issue":"07","key":"ref21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis","volume":"131","author":"R G Hart","year":"1999","journal-title":"Ann Intern Med"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.ahj.2008.01.023","article-title":"Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005","volume":"155","author":"K Jackson","year":"2008","journal-title":"Am Heart J"},{"issue":"8882","key":"ref23","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke","volume":"342","author":"EAFT (European Atrial Fibrillation Trial) Study Group","year":"1993","journal-title":"Lancet"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/dmd.31.3.294","article-title":"Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans","volume":"31","author":"U G Eriksson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"ref25","first-page":"S462","article-title":"Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials","volume":"10","author":"G W Albers","year":"2004","journal-title":"Am J Manag Care"},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.jacc.2005.07.062","article-title":"Trials an tribulations of non-inferiority: the ximelkagatran experience","volume":"46","author":"S Kaul","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"196","key":"ref27","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/978-3-642-00663-0_13","article-title":"Drug-induced liver injury in humans: The case of ximelagatran","author":"M Keisu","year":"2010","journal-title":"Handb Exp Pharmacol"},{"issue":"7400","key":"ref28","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/bmj.326.7400.1199","article-title":"How can research ethics committees protect patients better?","volume":"326","author":"S Garattini","year":"2003","journal-title":"BMJ"},{"issue":"20","key":"ref29","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1001\/jama.283.20.2701","article-title":"What makes clinical research ethical?","volume":"283","author":"E J Emanuel","year":"2000","journal-title":"JAMA"},{"issue":"07","key":"ref30","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jclinepi.2014.12.016","article-title":"Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor","volume":"68","author":"M E Flacco","year":"2015","journal-title":"J Clin Epidemiol"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/sim.1425","article-title":"Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics","volume":"22","author":"R B D'Agostino Sr","year":"2003","journal-title":"Stat Med"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"J P Piccini","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"ref33","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"S J Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"M R Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"ref35","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"C B Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"ref36","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"R P Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/clc.22081","article-title":"Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin","volume":"36","author":"A Dogliotti","year":"2013","journal-title":"Clin Cardiol"},{"issue":"9921","key":"ref38","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"C T Ruff","year":"2014","journal-title":"Lancet"},{"issue":"08","key":"ref39","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s11739-017-1678-9","article-title":"Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago","volume":"12","author":"G Palareti","year":"2017","journal-title":"Intern Emerg Med"},{"issue":"07","key":"ref40","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/CIRCULATIONAHA.110.007864","article-title":"Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation","volume":"124","author":"D Poli","year":"2011","journal-title":"Circulation"},{"issue":"04","key":"ref41","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10557-020-06981-3","article-title":"Anticoagulants for stroke prevention in atrial fibrillation in elderly patients","volume":"34","author":"A Sch\u00e4fer","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"issue":"9745","key":"ref42","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial","volume":"376","author":"L Wallentin","year":"2010","journal-title":"Lancet"},{"issue":"02","key":"ref43","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jacc.2016.03.600","article-title":"Achievements and limitations of evidence-based medicine","volume":"68","author":"D J Sheridan","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"9453","key":"ref44","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"P M Rothwell","year":"2005","journal-title":"Lancet"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.socscimed.2017.12.005","article-title":"Understanding and misunderstanding randomized controlled trials","volume":"210","author":"A Deaton","year":"2018","journal-title":"Soc Sci Med"},{"issue":"06","key":"ref46","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/joim.12197","article-title":"Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs","volume":"275","author":"T St\u00fcrmer","year":"2014","journal-title":"J Intern Med"},{"issue":"05","key":"ref47","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","article-title":"Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report","volume":"10","author":"L P Garrison Jr","year":"2007","journal-title":"Value Health"},{"issue":"07","key":"ref48","doi-asserted-by":"crossref","first-page":"e70962","DOI":"10.1002\/hsr2.70962","article-title":"The effects of health information technology on quality of care in emergency departments: A systematic review","volume":"8","author":"C S Kruse","year":"2025","journal-title":"Health Sci Rep"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(15)00257-4","article-title":"Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study","volume":"3","author":"W Ageno","year":"2016","journal-title":"Lancet Haematol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"D2","DOI":"10.1093\/eurheartj\/suv035","article-title":"Why do we need observational studies of everyday patients in the real-life setting?","volume":"17","author":"A T Cohen","year":"2015","journal-title":"Eur Heart J Suppl"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0041-1735628","article-title":"Thrombophilia, antithrombotic therapy, and recurrent pregnancy loss: A call for pragmatism in the face of unknowns","volume":"39","author":"G Piazza","year":"2021","journal-title":"Semin Reprod Med"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0140-6736(23)00693-1","article-title":"Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial","volume":"402","author":"S Quenby","year":"2023","journal-title":"Lancet"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0140-6736(23)02338-3","article-title":"Concerns about the ALIFE2 trial","volume":"403","author":"E Grandone","year":"2024","journal-title":"Lancet"},{"issue":"08","key":"ref54","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/humrep\/deab153","article-title":"Findings from a multicentre, observational study on reproductive outcomes in women with unexplained recurrent pregnancy loss: the OTTILIA registry","volume":"36","author":"E Grandone","year":"2021","journal-title":"Hum Reprod"},{"issue":"03","key":"ref55","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cpt.3733","article-title":"Optimizing patient registries for regulatory decision making - key learnings from an HMA\/EMA multistakeholder workshop","volume":"118","author":"K Plueschke","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"103728","DOI":"10.1016\/j.jbi.2021.103728","article-title":"Explainable automated coding of clinical notes using hierarchical label-wise attention networks and label embedding initialisation","volume":"116","author":"H Dong","year":"2021","journal-title":"J Biomed Inform"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"e56231","DOI":"10.2196\/56231","article-title":"Digital health literacy in patients with common chronic diseases: Systematic review and meta-analysis","volume":"27","author":"H Zaghloul","year":"2025","journal-title":"J Med Internet Res"},{"issue":"03","key":"ref58","first-page":"e75","article-title":"Research opportunities in stroke prevention for atrial fibrillation: A report from a National Heart, Lung, and Blood Institute Virtual Workshop","volume":"54","author":"A S Go","year":"2023","journal-title":"Stroke"},{"issue":"05","key":"ref59","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1159\/000546663","article-title":"Machine learning application for bleeding risk prediction in patients with atrial fibrillation treated with oral anticoagulation","volume":"148","author":"T T Lerman","year":"2025","journal-title":"Acta Haematol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1745-6215-13-214","article-title":"Quality of reporting of clinical non-inferiority and equivalence randomised trials\u2013update and extension","volume":"13","author":"P Schiller","year":"2012","journal-title":"Trials"},{"issue":"25","key":"ref61","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","article-title":"Randomized, controlled trials, observational studies, and the hierarchy of research designs","volume":"342","author":"J Concato","year":"2000","journal-title":"N Engl J Med"},{"issue":"25","key":"ref62","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJM200006223422506","article-title":"A comparison of observational studies and randomized, controlled trials","volume":"342","author":"K Benson","year":"2000","journal-title":"N Engl J Med"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4244\/EIJ-E-23-00023","article-title":"Observational studies play little role in guiding evidence-based medicine: Pros and cons","volume":"20","author":"P G Steg","year":"2024","journal-title":"EuroIntervention"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2716-5675.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T23:33:30Z","timestamp":1762040010000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2716-5675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":63,"URL":"https:\/\/doi.org\/10.1055\/a-2716-5675","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}